Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glucarpidase - BTG Specialty Pharmaceuticals

Next Previous
Drug Profile

Glucarpidase - BTG Specialty Pharmaceuticals

Alternative Names: Carboxypeptidase G2; CPG2; Megludase; OP 07; OP-07 - Ohara Pharmaceuticals; Voraxaze

Latest Information Update: 01 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Health Protection Agency Porton Down
  • Developer BTG Specialty Pharmaceuticals; Ohara Pharmaceutical; SERB Pharmaceuticals
  • Class Carboxypeptidases
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced damage

Most Recent Events

  • 30 Nov 2025 Launched for Chemotherapy-induced damage (In children, In adults, In infants, In adolescents) in Norway, Finland, Denmark, Hungary, Sweden (IV)
  • 30 Nov 2025 Glucarpidase is still in Registered phase for Chemotherapy-induced damage in European Union, Japan, Norway, Liechtenstein and Iceland
  • 20 Mar 2024 M8 Pharmaceuticals in-licenses glucarpidase (Voraxaze®) for marketing in Latin America

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top